These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 17915580)

  • 21. Neurological manifestations in lysosomal storage disorders - from pathology to first therapeutic possibilities.
    Hoffmann B; Mayatepek E
    Neuropediatrics; 2005 Oct; 36(5):285-9. PubMed ID: 16217702
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacological Chaperone Therapy: Preclinical Development, Clinical Translation, and Prospects for the Treatment of Lysosomal Storage Disorders.
    Parenti G; Andria G; Valenzano KJ
    Mol Ther; 2015 Jul; 23(7):1138-1148. PubMed ID: 25881001
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Personalized Pharmacoperones for Lysosomal Storage Disorder: Approach for Next-Generation Treatment.
    Haneef SA; Doss CG
    Adv Protein Chem Struct Biol; 2016; 102():225-65. PubMed ID: 26827607
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Advances in the treatment of lysosomal storage disease.
    Wraith JE
    Dev Med Child Neurol; 2001 Sep; 43(9):639-46. PubMed ID: 11570635
    [No Abstract]   [Full Text] [Related]  

  • 25. Gene therapy for lysosomal storage disorders.
    Ioannou YA; Enriquez A; Benjamin C
    Expert Opin Biol Ther; 2003 Aug; 3(5):789-801. PubMed ID: 12880379
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New therapeutic options for lysosomal storage disorders: enzyme replacement, small molecules and gene therapy.
    Beck M
    Hum Genet; 2007 Mar; 121(1):1-22. PubMed ID: 17089160
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lysosomal storage diseases.
    Platt FM; d'Azzo A; Davidson BL; Neufeld EF; Tifft CJ
    Nat Rev Dis Primers; 2018 Oct; 4(1):27. PubMed ID: 30275469
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lysosomal storage diseases: current therapies and future alternatives.
    Leal AF; Espejo-Mojica AJ; Sánchez OF; Ramírez CM; Reyes LH; Cruz JC; Alméciga-Díaz CJ
    J Mol Med (Berl); 2020 Jul; 98(7):931-946. PubMed ID: 32529345
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Therapy of lysosomal storage diseases: update and perspectives].
    Lara-Aguilar RA; Juárez-Vázquez CI; Medina-Lozano C
    Rev Invest Clin; 2011; 63(6):651-8. PubMed ID: 23650678
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination therapies for lysosomal storage disease: is the whole greater than the sum of its parts?
    Hawkins-Salsbury JA; Reddy AS; Sands MS
    Hum Mol Genet; 2011 Apr; 20(R1):R54-60. PubMed ID: 21421999
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gene therapy for lysosomal storage disorders.
    Barranger JM; Novelli EA
    Expert Opin Biol Ther; 2001 Sep; 1(5):857-67. PubMed ID: 11728220
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacotherapeutic strategies using small molecules for the treatment of glycolipid lysosomal storage disorders.
    Butters TD
    Expert Opin Pharmacother; 2007 Mar; 8(4):427-35. PubMed ID: 17309337
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment strategies for lysosomal storage disorders.
    Beck M
    Dev Med Child Neurol; 2018 Jan; 60(1):13-18. PubMed ID: 29090451
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of lysosomal storage diseases: recent patents and future strategies.
    Ortolano S; Viéitez I; Navarro C; Spuch C
    Recent Pat Endocr Metab Immune Drug Discov; 2014 Jan; 8(1):9-25. PubMed ID: 24433521
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment for Lysosomal Storage Disorders.
    Sheth J; Nair A
    Curr Pharm Des; 2020; 26(40):5110-5118. PubMed ID: 33059565
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting the central nervous system in lysosomal storage diseases: Strategies to deliver therapeutics across the blood-brain barrier.
    Critchley BJ; Gaspar HB; Benedetti S
    Mol Ther; 2023 Mar; 31(3):657-675. PubMed ID: 36457248
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stop-codon read-through for patients affected by a lysosomal storage disorder.
    Brooks DA; Muller VJ; Hopwood JJ
    Trends Mol Med; 2006 Aug; 12(8):367-73. PubMed ID: 16798086
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current strategies in the management of lysosomal storage diseases.
    Heese BA
    Semin Pediatr Neurol; 2008 Sep; 15(3):119-26. PubMed ID: 18708002
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The molecular basis of lysosomal storage diseases and their treatment.
    Winchester B; Vellodi A; Young E
    Biochem Soc Trans; 2000 Feb; 28(2):150-4. PubMed ID: 10816117
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting macrophages with baculovirus-produced lysosomal enzymes: implications for enzyme replacement therapy of the glycoprotein storage disorder galactosialidosis.
    Bonten EJ; Wang D; Toy JN; Mann L; Mignardot A; Yogalingam G; D'Azzo A
    FASEB J; 2004 Jun; 18(9):971-3. PubMed ID: 15084520
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.